Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MATHIAS

Financiado

Cerrado

New Molecular Functional Imaging Technologies and Therapeutic Strategies for The...

New Molecular Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis The development of novel technologies to diagnose and clinically treat invasive Aspergillus fumigatus infections is the scope of this research consortium. A. fumigatus is a ubiquitous mould whose spores are airborne and thus frequ... ver más

30/09/2018

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

0.00€ | Lider

TECHNICAL UNIVERSITY OF DENM...

N.D. | Participante

PSI

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2008-04145 DISEÑO, FABRICACION Y VALIDACION DE UN MICROARRAY PARA LA ID... 73K€ Cerrado

FUNGITECT Optimized Diagnostics for Improved Treatment Stratification... 8M€ Cerrado

CPP2021-008945 Desarrollo de dispositivos basados en ensayos de flujo later... 389K€ Cerrado

STRIFE Spatial and temporal regulation of the fungus host interacti... 2M€ Cerrado

SYBARIS Finding biomarkers of anti microbial drug resistance via a s... 6M€ Cerrado

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The development of novel technologies to diagnose and clinically treat invasive Aspergillus fumigatus infections is the scope of this research consortium. A. fumigatus is a ubiquitous mould whose spores are airborne and thus frequently inhaled. Humans with impaired immunity, e.g. those with haematological malignancies or bone marrow transplant recipients, are at a dramatically increased risk of severe, invasive A. fumigatus infection known as invasive aspergillosis (IA). IA is a rare disease in Europe but causes tremendous costs to the public health sector. Currently definitive diagnosis of IA is only obtained at autopsy or relies on invasive biopsy, an extremely unpleasant procedure which is not always applicable in suffering patients. Thus, a convenient, fast and specific diagnosis of IA is not available forcing clinicians to administer antifungal drugs on spec if a standard antibiotic treatment failed to reduce fever in risk patients. It would be of high financial benefit for clinics and has the potential to increase the survival rates of immuno-compromised patients, if a definitive diagnosis of IA could be obtained early and its response to treatment be monitored. This would allow applying the correct therapy at a dose and duration exactly tailored to patient needs. Equally important is the development of new treatment options which can replace existing systemic antifungal drugs with their known severe side effects. The approach of the consortium is to develop new disease specific tracers based on monoclonal antibodies along with the combined molecular imaging technologies PET/MR and PET/CT. Newly developed tracers shall then be functionalised by a combined labelling with radio-isotopes allowing diagnostic PET imaging but also immuno-radiotherapy, thus representing truly anti-infectious theranostics. This would provide a framework for new tools in the management not only of this rare but life-threatening mycosis but principally also for other infectious hazards.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores